Psyence Biomedical Invests in Psyence Labs for Ibogaine
The $2.6 million deal supports the development of pharmaceutical-grade ibogaine for clinical use in the United States.
Updated on Oct. 21, 2026 in Substance Abuse
Live Poll
Do you support increased investment in the development of pharmaceutical-grade ibogaine for mental health treatment?
Psyence Biomedical has completed a $2.6 million investment in Psyence Labs, securing a 43.37% stake in the company. This funding will advance a U.S.-based development program for pharmaceutical-grade ibogaine.
Why it matters
The investment strengthens the partnership between Psyence Biomedical and Texas Ibogaine Research Corporation, facilitating domestic development and grant opportunities. It also secures an exclusive supply chain for the U.S. clinical program.
Psyence Biomedical acquired 1,014 ordinary shares of PsyLabs at a price of $2,564 per share. The transaction results in a 43.37% equity stake in the company.
The players
Psyence Biomedical
This life sciences company focuses on the development of psilocybin and other psychedelic medicines.
Psyence Labs
This entity specializes in the research and production of psychedelic compounds for clinical applications.
Texas Ibogaine Research Corporation
This organization manages ibogaine development efforts and manufacturing partnerships within the state of Texas.
Benuvia Operations
This company operates a specialized, DEA-registered manufacturing facility located in Round Rock.
The details
The collaboration utilizes a manufacturing agreement with Benuvia Operations, which runs a DEA-registered facility in Round Rock. This deal also includes an ibogaine regulatory readiness package to streamline the development process.
Timeline
September 23, 2026: Psyence BioMed agreed to invest up to $5 million.
September 28, 2026: Binding term sheet announced for TIRC and PsyLabs.
October 1, 2026: Share exchange between the companies closed.
October 5, 2026: Manufacturing agreement details announced.
November 30, 2026: Deadline for definitive license and supply agreement.
The Big Picture
The project follows the strict regulatory requirements set by the Controlled Substances Act by partnering with a DEA-registered manufacturer. This compliance is essential for any firm seeking to advance the development of Schedule I substances in a clinical setting.
The development program aims to provide a path for pharmaceutical-grade ibogaine, potentially expanding future treatment options. However, availability remains limited to clinical research environments and is not currently open to the general public.
The takeaway
This partnership leverages local manufacturing capabilities to accelerate the production of regulated substances for research purposes. Readers should monitor future clinical trial updates to understand when these treatments may progress toward broader medical applications.
What happens next
The companies are scheduled to finalize a definitive license and supply agreement by November 30, 2026.
Further reading
Learn more about the evolving landscape of Substance Abuse treatments and clinical research.
Live Poll
Do you support increased investment in the development of pharmaceutical-grade ibogaine for mental health treatment?
